KMTS trades 13.8% above Wall Street's consensus target of $24.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes KMTS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Kestra Medical Technologies, Ltd. (KMTS) has a Wall Street consensus price target of $24.00, based on estimates from 4 covering analysts. With the stock currently trading at $27.85, this represents a potential downside of -13.8%. The company has a market capitalization of $1.63B.
Analyst price targets range from a low of $24.00 to a high of $24.00, representing a 0% spread in expectations. The median target of $24.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, KMTS trades at a trailing P/E of -5.4x. Analysts expect EPS to grow +14.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
MDTMedtronic plc | $107.6B | $83.83 | $95.80 | +14.3% | Buy | 14.1x | 51 |
ABTAbbott Laboratories | $166.9B | $95.84 | $125.62 | +31.1% | Buy | 17.5x | 41 |
BSXBoston Scientific Corporation | $67.3B | $45.30 | $82.40 | +81.9% | Buy | 13.5x | 44 |
EWEdwards Lifesciences Corporation | $54.6B | $94.82 | $97.45 | +2.8% | Buy | 31.5x | 48 |
LIVNLivaNova PLC | $4.6B | $83.58 | $81.43 | -2.6% | Buy | 19.7x | 15 |
NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
AVNSAvanos Medical, Inc. | $1.2B | $24.92 | $23.00 | -7.7% | Hold | 24.9x | 8 |
IRTCiRhythm Technologies, Inc. | $4.1B | $125.09 | $188.75 | +50.9% | Buy | — | 20 |
BEATHeartBeam, Inc. | $23M | $0.66 | — | — | — | — | — |
TXNTexas Instruments Incorporated | $267.0B | $293.30 | $281.56 | -4.0% | Buy | 38.1x | 65 |
Quick answers to the most common questions about buying KMTS stock.
KMTS's consensus price target is $24, -13.8% below the current price of $27.85. The 4 analysts tracking KMTS see downside risk at present valuations.
KMTS has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $24 implies -13.8% downside from current levels.
KMTS's current price is $27.85 with a consensus target of $24 (-13.8% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $24 for KMTS, while the most conservative target is $24. The consensus of $24 represents the median expectation. These targets typically reflect 12-month expectations.
KMTS is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month KMTS stock forecast based on 4 Wall Street analysts shows a consensus price target of $24, with estimates ranging from $24 (bear case) to $24 (bull case). The median consensus rating is "Buy".
Analysts are cautious on KMTS, with 0 Sell ratings and a price target of $24 (-13.8% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
KMTS analyst price targets range from $24 to $24, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $24 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.